Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome

Lupus
C M YelnikNathalie Costedoat-Chalumeau

Abstract

Purpose The purpose of this study was to evaluate the safety of antithrombotic treatments prescribed during pregnancy in patients with antiphospholipid syndrome (APS). Methods This international, multicenter study included two cohorts of patients: a retrospective French cohort and a prospective US cohort (PROMISSE study). Inclusion criteria were (1) APS (Sydney criteria), (2) live pregnancy at 12 weeks of gestation (WG) with (3) follow-up data until six weeks post-partum. According to APS standard of care, patients were treated with aspirin and/or low-molecular weight heparin (LMWH) at prophylactic (pure obstetric APS) or therapeutic doses (history of thrombosis). Major bleeding was defined as abnormal blood loss during the pregnancy and/or post-partum period requiring intervention for hemostasis or transfusion, or during the peripartum period greater than 500 mL and/or requiring surgery or transfusion. Other bleeding events were classified as minor. Results Two hundred and sixty-four pregnancies (87 prospectively collected) in 204 patients were included (46% with history of thrombosis, 23% with associated systemic lupus). During pregnancy, treatment included LMWH ( n = 253; 96%) or low-dose aspirin ( n = 223; 84%), and 215 (81...Continue Reading

References

Apr 16, 2002·Arthritis and Rheumatism·Ricard CerveraUNKNOWN Euro-Phospholipid Project Group
Sep 26, 2012·Chronobiology International·Diana E AyalaRamón C Hermida
May 17, 2013·Rheumatology·Guillaume HanounaNathalie Costedoat-Chalumeau
Dec 3, 2014·Journal de gynécologie, obstétrique et biologie de la reproduction·C Deneux-TharauxJ Tort
Jun 23, 2015·Annals of Internal Medicine·Jill P BuyonJane E Salmon
Jan 16, 2016·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Marion E van HoornUNKNOWN FRUIT Investigators

❮ Previous
Next ❯

Citations

Jan 16, 2020·The Journal of International Medical Research·Jae Won KimDong Ho Park
Jan 27, 2021·Journal of Korean Medical Science·Eunyoung Emily LeeEun Bong Lee
Feb 19, 2021·Expert Opinion on Drug Safety·Anna Viola TaulaigoLaura Andreoli
Feb 22, 2021·Fertility and Sterility·Diana AlecsandruJason M Franasiak
Apr 13, 2021·Journal of Reproductive Immunology·Jingjing Yang, Meiying Liang
Sep 15, 2021·Current Opinion in Rheumatology·Mehret Birru TalabiMegan E B Clowse

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Software Mentioned

SAS

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

© 2022 Meta ULC. All rights reserved